Welcome to our dedicated page for Heartbeam SEC filings (Ticker: BEATW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Heartbeam's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Heartbeam's regulatory disclosures and financial reporting.
HeartBeam, Inc. reported another quarter of losses with no revenue and highlighted serious liquidity concerns. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $4.7 million, narrower than the $5.5 million loss a year earlier. Operating expenses were $4.7 million, with selling, general and administrative costs rising 17% and research and development falling 32% as product development and consulting spending declined.
Cash and cash equivalents were $2.0 million as of March 31, 2026, and management stated this is insufficient to fund operations for the next twelve months, raising “substantial doubt” about the company’s ability to continue as a going concern. Subsequent to quarter-end, HeartBeam completed an underwritten offering of 14,375,000 shares of common stock for gross proceeds of approximately $11.5 million. The company remains pre-revenue despite FDA clearances for its 3D ECG telehealth system and is beginning a limited commercial launch and multiple pilot studies, while expecting no material commercial revenue in 2026.
HeartBeam, Inc. reported another quarter of losses with no revenue and highlighted serious liquidity concerns. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $4.7 million, narrower than the $5.5 million loss a year earlier. Operating expenses were $4.7 million, with selling, general and administrative costs rising 17% and research and development falling 32% as product development and consulting spending declined.
Cash and cash equivalents were $2.0 million as of March 31, 2026, and management stated this is insufficient to fund operations for the next twelve months, raising “substantial doubt” about the company’s ability to continue as a going concern. Subsequent to quarter-end, HeartBeam completed an underwritten offering of 14,375,000 shares of common stock for gross proceeds of approximately $11.5 million. The company remains pre-revenue despite FDA clearances for its 3D ECG telehealth system and is beginning a limited commercial launch and multiple pilot studies, while expecting no material commercial revenue in 2026.
HeartBeam, Inc. director Richard Ferrari increased his stake by purchasing 57,500 shares of common stock at $0.80 per share. The buy was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners acted as sole bookrunner.
This amended Form 4 corrects Ferrari’s previously reported acquisition and total beneficial ownership. The original filing mistakenly showed 62,500 shares acquired; the correct figure is 57,500 shares. Following this transaction, Ferrari beneficially owns 286,636 shares of HeartBeam common stock directly.
HeartBeam, Inc. director Richard Ferrari increased his stake by purchasing 57,500 shares of common stock at $0.80 per share. The buy was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners acted as sole bookrunner.
This amended Form 4 corrects Ferrari’s previously reported acquisition and total beneficial ownership. The original filing mistakenly showed 62,500 shares acquired; the correct figure is 57,500 shares. Following this transaction, Ferrari beneficially owns 286,636 shares of HeartBeam common stock directly.
HeartBeam, Inc. CFO Tim Cruickshank increased his stake by buying 31,250 shares of common stock at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock.
The offering priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners, a division of American Capital Partners, acting as sole bookrunner. After this transaction, Cruickshank directly owns 72,230 shares, including 23,333 RSUs that have vested.
HeartBeam, Inc. CFO Tim Cruickshank increased his stake by buying 31,250 shares of common stock at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock.
The offering priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners, a division of American Capital Partners, acting as sole bookrunner. After this transaction, Cruickshank directly owns 72,230 shares, including 23,333 RSUs that have vested.
HeartBeam, Inc. director Willem Elfrink reported an open-market purchase of common stock. On April 16, 2026, he bought 187,500 shares at $0.80 per share, bringing his direct holdings to 538,667 shares.
According to the footnote, these shares were purchased in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners acting as sole bookrunner.
HeartBeam, Inc. director Willem Elfrink reported an open-market purchase of common stock. On April 16, 2026, he bought 187,500 shares at $0.80 per share, bringing his direct holdings to 538,667 shares.
According to the footnote, these shares were purchased in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners acting as sole bookrunner.
HeartBeam, Inc. director-associated entity Open Book Healthcare purchased 31,250 shares of common stock in an open-market transaction on April 16, 2026, at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026. Following this transaction, 31,250 shares are held indirectly for the benefit of Michael R. Jaff through Open Book Healthcare.
HeartBeam, Inc. director-associated entity Open Book Healthcare purchased 31,250 shares of common stock in an open-market transaction on April 16, 2026, at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026. Following this transaction, 31,250 shares are held indirectly for the benefit of Michael R. Jaff through Open Book Healthcare.
HeartBeam, Inc. director Branislav Vajdic made an open-market purchase of 31,250 shares of common stock at $0.80 per share. After this transaction, he directly owns 909,914 shares.
The shares were bought in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners, a division of American Capital Partners, acted as sole bookrunner. The offering priced on April 14, 2026 and closed on April 16, 2026.
HeartBeam, Inc. director Branislav Vajdic made an open-market purchase of 31,250 shares of common stock at $0.80 per share. After this transaction, he directly owns 909,914 shares.
The shares were bought in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners, a division of American Capital Partners, acted as sole bookrunner. The offering priced on April 14, 2026 and closed on April 16, 2026.
HeartBeam, Inc. director Richard Ferrari reported an open-market purchase of 62,500 shares of common stock at $0.80 per share. Following this buy, he directly holds 291,636 shares. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, which priced on April 14, 2026 and closed on April 16, 2026.
HeartBeam, Inc. director Richard Ferrari reported an open-market purchase of 62,500 shares of common stock at $0.80 per share. Following this buy, he directly holds 291,636 shares. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, which priced on April 14, 2026 and closed on April 16, 2026.
HeartBeam, Inc. entered an underwriting agreement with Titan Partners Group for an underwritten public offering of 12,500,000 shares of common stock at a public price of $0.80 per share, raising approximately $10.0 million in gross proceeds upon closing.
The underwriter will purchase shares at $0.744 per share and holds a 30‑day option to buy up to 1,875,000 additional shares to cover over‑allotments. HeartBeam will also issue underwriter warrants equal to 5% of the total shares sold, exercisable immediately for five years.
The company and its officers and directors agreed to a 75‑day lock‑up on specified securities. Net proceeds are intended to support commercialization of its FDA‑cleared 12‑lead synthesized ECG system, development of its extended‑wear patch and heart attack detection initiatives, enhancement of AI capabilities, and working capital and general corporate purposes.
HeartBeam, Inc. entered an underwriting agreement with Titan Partners Group for an underwritten public offering of 12,500,000 shares of common stock at a public price of $0.80 per share, raising approximately $10.0 million in gross proceeds upon closing.
The underwriter will purchase shares at $0.744 per share and holds a 30‑day option to buy up to 1,875,000 additional shares to cover over‑allotments. HeartBeam will also issue underwriter warrants equal to 5% of the total shares sold, exercisable immediately for five years.
The company and its officers and directors agreed to a 75‑day lock‑up on specified securities. Net proceeds are intended to support commercialization of its FDA‑cleared 12‑lead synthesized ECG system, development of its extended‑wear patch and heart attack detection initiatives, enhancement of AI capabilities, and working capital and general corporate purposes.
HeartBeam, Inc. is offering [●] shares of Common Stock and, in lieu of shares that would push a purchaser above a 4.99% ownership cap, pre-funded warrants exercisable for one share (exercise price $0.001). The offering is underwritten on a firm commitment basis and includes an up to 30-day, up-to-30% over-allotment option. The company holds two FDA clearances for its cable-free, synthesized 12-lead ECG system (arrhythmia assessment) and recently announced a commercial LOI with ClearCardio, enrollment in the ALIGN-ACS ER study, and a working prototype of a 12L patch. Management and auditors have expressed substantial doubt about the company’s ability to continue as a going concern.
HeartBeam, Inc. is offering [●] shares of Common Stock and, in lieu of shares that would push a purchaser above a 4.99% ownership cap, pre-funded warrants exercisable for one share (exercise price $0.001). The offering is underwritten on a firm commitment basis and includes an up to 30-day, up-to-30% over-allotment option. The company holds two FDA clearances for its cable-free, synthesized 12-lead ECG system (arrhythmia assessment) and recently announced a commercial LOI with ClearCardio, enrollment in the ALIGN-ACS ER study, and a working prototype of a 12L patch. Management and auditors have expressed substantial doubt about the company’s ability to continue as a going concern.
HeartBeam, Inc. director Marga Ortigas-Wedekind received a grant of stock options representing the right to buy 44,827 shares of common stock at an exercise price of $1.43 per share. This is a compensation-related award, not an open-market share purchase or sale.
According to the grant terms, one half of the options, covering 22,413.5 underlying shares, will vest on March 31, 2026, and the remaining half will vest on June 30, 2026. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and expire on January 1, 2036, giving the director a long-term incentive tied to the company’s share performance.
HeartBeam, Inc. director Marga Ortigas-Wedekind received a grant of stock options representing the right to buy 44,827 shares of common stock at an exercise price of $1.43 per share. This is a compensation-related award, not an open-market share purchase or sale.
According to the grant terms, one half of the options, covering 22,413.5 underlying shares, will vest on March 31, 2026, and the remaining half will vest on June 30, 2026. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and expire on January 1, 2036, giving the director a long-term incentive tied to the company’s share performance.